Bruton's tyrosine kinase

Brutons Tyrosine Kinase (BTK) Inhibitors Drug Pipeline Market Report 2022: Comprehensive Insights About 30+ Companies and 30+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 10, 2022
Health, Pharmaceutical, Mantle cell lymphoma, Chronic lymphocytic leukemia, Patient, Food, BTK, Pemphigus, Waldenström's macroglobulinemia, B-cell lymphoma, Shanda, Clinical trial, ITP, Bruton's tyrosine kinase, Adult, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Technology, FDA, Pemphigus foliaceus, Pemphigus vulgaris, Waldenström, European Commission, Acquisition, NDA, BeiGene, Lymphocytosis, Degenerative disease, Inhibitor, Discovery, News, Royal commission, II, Pharmaceutical industry

This "Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape.

Key Points: 
  • This "Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape.
  • A detailed picture of the Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape is provided which includes the disease overview and Brutons Tyrosine Kinase (BTK) Inhibitors treatment guidelines.
  • Brutons Tyrosine Kinase (BTK) Inhibitors: Therapeutic Assessment
    This segment of the report provides insights about the different Brutons Tyrosine Kinase (BTK) Inhibitors drugs segregated based on following parameters that define the scope of the report.
  • The companies which have their Brutons Tyrosine Kinase (BTK) Inhibitors drug candidates in the most advanced stage, i.e.

Brutons Tyrosine Kinase (BTK) Inhibitors Pipeline Insight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 17, 2021
Health, Pharmaceutical, Bruton's tyrosine kinase, NDA, Therapy, Acquisition, BTK, Technology, Inhibitor, Mergers and acquisitions, Pharmaceutical industry

The "Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2021 report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape.
  • "Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2021" outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape is provided which includes the disease overview and Brutons Tyrosine Kinase (BTK) Inhibitors treatment guidelines.

Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Tyrosine kinases, Multiple sclerosis, Life sciences, Bruton's tyrosine kinase, Biology, Glial cells, Tyrosine kinase, Multiple sclerosis research, Microglia, Biogen, Protein kinase inhibitor

For over 30 years, Biogen has led in MS research and today has a leading portfolio of MS products.

Key Points: 
  • For over 30 years, Biogen has led in MS research and today has a leading portfolio of MS products.
  • BTK inhibitors may have the potential to transform the treatment paradigm of autoimmune diseases, in particular MS.
  • Orelabrutinib is a small molecule Brutons tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and in development for the potential treatment of autoimmune diseases.
  • Among myeloid cells expressing BTK, microglia, which reside in the CNS, have been shown to express high level of BTK in multiple sclerosis.

InnoCare Announces Breakthrough Therapy Designation of Orelabrutinib by US FDA for Treatment of R/R MCL

Retrieved on: 
Monday, June 28, 2021
Tyrosine kinases, Bruton's tyrosine kinase, Branches of biology, Tyrosine kinase, Mantle cell lymphoma, Tyrosine kinase inhibitors, Orphan drugs, Drugs

BEIJING, June 28, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL).

Key Points: 
  • BEIJING, June 28, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL).
  • Orelabrutinib is a highly selective BTK inhibitor targeting both B-cell malignancy and autoimmune diseases.
  • Dr. Jasmine Cui, the co-founder, chairwoman and CEO of InnoCare said, "We are very proud that orelabrutinib was granted BTD after obtaining Orphan Drug Designation.
  • InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases.

TG Therapeutics Announces Preclinical and Clinical Data Evaluating TG-1701 at the 16th International Congress on Malignant Lymphoma

Retrieved on: 
Friday, June 18, 2021
Bruton's tyrosine kinase, Branches of biology

NEW YORK, June 18, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from two presentations evaluating TG-1701, the Companys investigational once-daily, oral BTK inhibitor, presented today during the 16th International Congress on Malignant Lymphoma (ICML).

Key Points: 
  • NEW YORK, June 18, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from two presentations evaluating TG-1701, the Companys investigational once-daily, oral BTK inhibitor, presented today during the 16th International Congress on Malignant Lymphoma (ICML).
  • The Phase 1 data presented today were previously presented at the 2021 American Society of Clinical Oncology (ASCO) annual meeting and the 2021 European Hematology Association annual meeting.
  • TG-1701 is a novel irreversible BTK inhibitor currently in Phase 1 clinical development, as monotherapy or in combination with ublituximab and UKONIQ (umbralisib).
  • In patient samples from a Phase 1 clinical trial of TG-1701, phosphoproteomic analysis differentiated early and late CLL responders to TG-1701 therapy.

Bruton's Tyrosine Kinase (BTK) Inhibitor Pipeline Insight Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 14, 2021
Pharmaceutical, Science, Health, Research, Bruton's tyrosine kinase, Tyrosine kinase, BTK, Branches of biology, Btk-type zinc finger

The "Bruton's Tyrosine Kinase (BTK) Inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bruton's Tyrosine Kinase (BTK) Inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Bruton's Tyrosine Kinase (BTK) Inhibitor - Pipeline Insight, 2021," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Bruton's Tyrosine Kinase (BTK) Inhibitor pipeline landscape.
  • Bruton's Tyrosine Kinase (BTK) Inhibitor: Therapeutic Assessment
    This segment of the report provides insights about the different Bruton's Tyrosine Kinase (BTK) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Bruton's Tyrosine Kinase (BTK) Inhibitor: Pipeline Development Activities
    The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage.

European Hematology Association - ALPINE Study Reveals Superior Safety and Efficacy of Zanubrutinib Compared with Ibrutinib

Retrieved on: 
Friday, June 11, 2021
Orphan drugs, Chemical compounds, Breakthrough therapy, Piperidines, Drugs, Health sciences, Tyrosine kinase inhibitors, Tyrosine kinases, Bruton's tyrosine kinase, Ibrutinib, Zanubrutinib

Zanubrutinib is a next-generation BTK inhibitor that is designed for potent and sustained inhibition of BTK while minimizing the off-target effects of first-generation inhibitors such as ibrutinib.

Key Points: 
  • Zanubrutinib is a next-generation BTK inhibitor that is designed for potent and sustained inhibition of BTK while minimizing the off-target effects of first-generation inhibitors such as ibrutinib.
  • The activity and tolerability of zanubrutinib have been demonstrated in patients with CLL/SLL in early phase clinical trials.
  • The ALPINE study solidifies the findings of these pivotal trials by a head-to-head comparison of the safety and efficacy of zanubrutinib and ibrutinib in 415 patients with relapsed/refractory CLL/SLL.
  • In summary, zanubrutinib showed more selective inhibition of BTK resulting in improved efficacy and safety compared with ibrutinib.

European Hematology Association - ALPINE Study Reveals Superior Safety and Efficacy of Zanubrutinib Compared with Ibrutinib

Retrieved on: 
Friday, June 11, 2021
Orphan drugs, Chemical compounds, Breakthrough therapy, Piperidines, Drugs, Health sciences, Tyrosine kinase inhibitors, Tyrosine kinases, Bruton's tyrosine kinase, Ibrutinib, Zanubrutinib

Zanubrutinib is a next-generation BTK inhibitor that is designed for potent and sustained inhibition of BTK while minimizing the off-target effects of first-generation inhibitors such as ibrutinib.

Key Points: 
  • Zanubrutinib is a next-generation BTK inhibitor that is designed for potent and sustained inhibition of BTK while minimizing the off-target effects of first-generation inhibitors such as ibrutinib.
  • The activity and tolerability of zanubrutinib have been demonstrated in patients with CLL/SLL in early phase clinical trials.
  • The ALPINE study solidifies the findings of these pivotal trials by a head-to-head comparison of the safety and efficacy of zanubrutinib and ibrutinib in 415 patients with relapsed/refractory CLL/SLL.
  • In summary, zanubrutinib showed more selective inhibition of BTK resulting in improved efficacy and safety compared with ibrutinib.

BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021

Retrieved on: 
Friday, June 11, 2021
Health, Science, Pharmaceutical, Research, Oncology, Health sciences, Health, BeiGene, Monoclonal antibodies, Bruton's tyrosine kinase, Novartis, Clinical trial, Tislelizumab, Tislelizumab, BRUKINSA, BeiGene, TISLELIZUMAB, BRUKINSA, BEIGENE

And in the two BRUKINSA trials, our selective next-generation BTK inhibitor showed sustained deep responses and remained well-tolerated in these patients.

Key Points: 
  • And in the two BRUKINSA trials, our selective next-generation BTK inhibitor showed sustained deep responses and remained well-tolerated in these patients.
  • The 35-month follow-up results from the single-arm, open-label, multicenter pivotal Phase 2 trial (NCT03206970) demonstrated BRUKINSAs long-term benefit and tolerability for patients with R/R MCL.
  • BeiGene has initiated or completed 17 potentially registration-enabling clinical trials in China and globally, including 13 Phase 3 trials and four pivotal Phase 2 trials.
  • BeiGene has also entered into a collaboration with Novartis granting Novartis rights to develop, manufacture, and commercialize tislelizumab in North America, Europe, and Japan.

Two-year data from the TOBA II BTK clinical trial demonstrate durability of dissection repair below the knee with the Philips Tack Endovascular System

Retrieved on: 
Thursday, June 3, 2021
Medicine, Clinical medicine, Health sciences, Bruton's tyrosine kinase, Angioplasty, TIMI, Clinical trial, Revascularization, Osteochondritis dissecans

Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced positive two-year results from the Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) clinical trial.

Key Points: 
  • Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced positive two-year results from the Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) clinical trial.
  • Across all patients in the TOBA II BTK clinical trial at two years, 73.6% had freedom from clinically driven target lesion revascularization (CD-TLR) and did not require a repeat procedure for the treated artery segment.
  • These positive two-year data reiterate the clinical importance of below-the-knee dissection repair and validates the sustained durability of Tack-optimized interventions.
  • The two-year TOBA II BTK data also show sustained improvement in patients quality of life.